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Abstract: Coenzyme Q (CoQ) is a vital lipophilic molecule that is endogenously synthesized in
the mitochondria of each cell. The CoQ biosynthetic pathway is complex and not completely
characterized, and it involves at least thirteen catalytic and regulatory proteins. Once it is synthesized,
CoQ exerts a wide variety of mitochondrial and extramitochondrial functions thank to its redox
capacity and its lipophilicity. Thus, low levels of CoQ cause diseases with heterogeneous clinical
symptoms, which are not always understood. The decreased levels of CoQ may be primary caused
by defects in the CoQ biosynthetic pathway or secondarily associated with other diseases. In both
cases, the pathomechanisms are related to the CoQ functions, although further experimental evidence
is required to establish this association. The conventional treatment for CoQ deficiencies is the high
doses of oral CoQ10 supplementation, but this therapy is not effective for some specific clinical
presentations, especially in those involving the nervous system. To better understand the CoQ
biosynthetic pathway, the biological functions linked to CoQ and the pathomechanisms of CoQ
deficiencies, and to improve the therapeutic outcomes of this syndrome, a variety of animal models
have been generated and characterized in the last decade. In this review, we show all the animal
models available, remarking on the most important outcomes that each model has provided. Finally,
we also comment some gaps and future research directions related to CoQ metabolism and how the
current and novel animal models may help in the development of future research studies.
Keywords: preclinical models; pathomechanisms; therapy; mitochondria; mitochondrial disease;
bioenergetics; oxidative stress; sulfide metabolism
1. Introduction
Coenzyme Q (CoQ) or ubiquinone is an essential lipid present in almost all living
organisms. CoQ is composed of a benzoquinone ring and a polyisoprene chain of variable
length. Each specie has a major CoQ form attending to the length of the polyisoprene chain,
i.e., 10 isoprene units (CoQ10) in humans, zebrafish (Danio rerio), and Schizosaccharomyces
pombe, 9 units (CoQ9) in mice, Caenorhabditis elegans and plants, 8 units (CoQ8) in Escherichia
coli, and 6 units (CoQ6) in Saccharomyces cerevisiae [1,2]. Although one form of CoQ is
dominant in each organism, a minor form of CoQ can be also detected in some species, e.g.,
CoQ9 in humans or CoQ10 in mice [3].
Thanks to its redox chemistry, CoQ participates in the mitochondrial respiration,
accepting electrons from complex I or complex II and transferring them to complex III at
the same time that a proton gradient is produced in the intermembrane space [4,5]. This
proton motive force is used by the ATP synthase to produce the final ATP molecule. More-
over, CoQ is a cofactor for different mitochondrial dehydrogenases involved in different
metabolic pathways [1,4,6], including the following: the dihydroorotate dehydrogenase
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(DHODH), involved in the pyrimidine biosynthesis [7,8]; the mitochondrial glycerol-3-
phosphate dehydrogenase (G3PDH), linking glycolysis, oxidative phosphorylation, and
fatty acid metabolism [9,10]; the electron transport flavoprotein dehydrogenase (ETFDH),
involved in fatty acid β-oxidation, the catabolism of several amino acids, and sarcosine
metabolism [11,12]; the proline dehydrogenase (PRODH) and proline dehydrogenase 2
(PRODH2) required for proline, glyoxylate, and arginine metabolism [6,13]; the choline
dehydrogenase (CHDH) related to glycine metabolism [14]; and the sulfide-quinone ox-
idoreductase (SQOR) that catalyzes the first reaction required for the detoxification of
hydrogen sulfide (H2S) [15] (Figure 1a).
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Uncoupling proteins (UCPs) are other mitochondrial components susceptible to be
regulated by redox reactions. Some experi ental evidence has suggested that CoQ is a
cofactor for UCPs, connecting CoQ with the control of thermogenesis [16,17] and with an
alternative mechanism for decreasing reactive oxygen species (ROS) inside mitochondria
via UCPs–superoxide interaction [18]. However, controversial results have been reported
on the involvement of CoQ in the regulation of the UCPs [17,19]. Other studies i vestigated
the r gulation of the mitochondrial permeability transition pore (PTP) by ubiquinone ana-
logues [20,21]. Experimental evidence suggests that quinones modulate the PTP through a
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common binding site rather than through redox reactions. CoQ seems also to prevent PTP
opening [22], but further studies are required to understand whether CoQ has a primary
function in the PTP. Recently, two studies reported that CoQ could also act as a cofactor
for the ferroptosis suppressor protein 1 (FSP1) (previously known as apoptosis-inducing
factor mitochondrial 2, AIFM2), thus contributing to the suppression of ferroptosis, an
iron-dependent form of cell death with increased oxidative damage [23,24] (Figure 1b).
In addition to these metabolic roles related to mitochondria, CoQ is a crucial an-
tioxidant that specially acts in the lipid membranes. The antioxidant capacity of CoQ is
due to its capability to directly reduce reactive oxygen species (ROS) but also to regen-
erate other antioxidants, e.g., tocopherol and ascorbate [2,6,25,26]. Moreover, different
non-mitochondrial functions of CoQ have been identified, and extensive reviews of these
actions have been published elsewhere [1,27,28].
The synthesis of CoQ mainly occurs in the mitochondrial inner membrane by a
set of nuclear-encoded COQ proteins through a biochemical pathway that is not com-
pletely understood [2,4,10,25,29] (Figure 2a). However, some authors have also located
the synthesis of CoQ outside the mitochondria, specifically in the endoplasmic reticulum
(ER)–Golgi system [30,31]. Moreover, a study in yeast demonstrated the role of the en-
doplasmic reticulum–mitochondria encounter structure (ERMES) in the coordination of
CoQ biosynthesis in mitochondria, highlighting the importance of the communication
between these two organelles [32]. The CoQ biosynthetic process in the mitochondria
is similar in prokaryotes and eukaryotes: a long polyisoprenoid lipid tail is coupled to
a benzenoid precursor, and the benzenoid ring is further modified through successive
steps to yield the final product [2,33,34]. 4-Hydroxybenzoic acid (4-HB) is the precursor
of the benzoquinone ring of CoQ [35], although some other alternative ring precursors
are being postulated [2]. For the biosynthesis of 4-HB, human cells utilize phenylalanine
or tyrosine as ring precursors [29]. The isoprene carbon units for making the CoQ side-
chain are derived from the mevalonate pathway in eukaryotes and some prokaryotes [36].
The lipophilic polyprenyl tail is synthesized by the addition of dimethylallyl pyrophos-
phate (DMAPP) and isopentenyl pyrophosphate (IPP) by PDSS1/PDSS2 in humans and
mice. Consequently, the heterotetramer PDSS1/PDSS2 is responsible for the length of
the polyprenyl tail [29,36,37]. Then, COQ2 in mammals catalyze the attachment of the
polyisoprenoid tail to the ring precursor. From this step, a total of seven reactions (one
decarboxylation, three hydroxylation, and three methylation) produce the fully substituted
benzoquinone ring of CoQ [35]: C5-hydroxylation (human COQ6), O-methylations (human
COQ3), C1-hydroxilation and C1-decarboxylation (unidentified), C2-methylation (human
COQ5), and C6-hydroxilation (human COQ7) [4,38–41]. In addition to the enzymes with
catalytic activity in the CoQ biosynthetic pathway, there are additional proteins necessary
for CoQ synthesis, although their exact functions are not well established. However, the
disruption in any of them produce a reduction in the CoQ levels. In humans, these proteins
are COQ4, COQ8A (also known as ADCK3), COQ8B (also known as ADCK4), COQ9,
COQ10A, and COQ10B [42–47]. Some of the biosynthetic proteins are assembled into a
high molecular mass complex, named complex Q, with the objective of improving the
catalytic efficiency of the CoQ biosynthetic pathway and minimizing the escape of interme-
diates [4,29,37] (Figure 2b). The benzoquinone ring of CoQ can be found in its completely
oxidized form (ubiquinone, CoQ), in the semireduced form (ubisemiquinone, CoQH•),
and in the completely reduced form (ubiquinol, CoQH2) after receiving two electrons [1,4]
(Figure 2c).
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CoQ levels can be severely reduced in a group of mitochondrial diseases named
CoQ deficiencies, which are clinically and genetically heterogeneous disorders. Five ma-
jor phenotypes have been described: (1) encephalomyopathy (recurrent myoglobinuria,
encephalopathy, and mitochondrial myopathy); (2) cerebellar ataxia (cerebellar atrophy
ssociate with other neurologic manifestations and, occ sionally, endocrine dysfunc-
tions); (3) infantile multisystemic form; (4) isolated myopathy, characterized by muscle
weakness, myoglobinuria, exercise intolerance, and elevated creatine kinase (CK); and (5)
nephropathy. Growth retardation, deafness, hearing loss, and cardiomyopathy have also
been described in CoQ10-deficient patients [48]. This heterogeneity in the clinical presenta-
tions suggests the existence of multiple pathomechanisms, which could be theoretically
due to the multiple functional roles of CoQ and the complexity of the CoQ biosynthetic
pathway, although further experimental evidences are required to understand the diseases’
conditions and tissue-specific pathomec anis s. Pr mary CoQ deficiency is caused by
a tosomal rec ssive utations in CoQ genes [48], while secondary CoQ eficiency is
produced by mutations in genes unrelated to CoQ biosynthesis or is derived from other
physiological processes or pharmacological treatments [49,50]. Mutations or deletions
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in 10 genes involved in the CoQ biosynthetic pathway have been reported in humans:
PSSS1 [51], PDSS2 [52], COQ2 [51,53,54], COQ4 [55], COQ5 [56], COQ6 [57], COQ7 [58,59],
COQ8A (or ADCK3) [60,61], COQ8B (or ADCK4) [62,63], and COQ9 [64,65]. The secondary
forms are probably more frequent, and they include patients with ataxia and oculomotor
apraxia due to mutations in the aprataxin (APTX) gene [66–68]; with isolated myopathy due
to mutations in the electron-transferring-flavoprotein dehydrogenase gene (ETFDH) [69];
and with cardiofaciocutaneous (CFC) syndrome due to mutations in BRAF [70]. Moreover,
CoQ10 deficiency has been reported in association with pathogenic mitochondrial DNA
(mtDNA) depletion, deletions, or point mutations [71–73]. In addition, secondary CoQ
deficiency has been linked to a decrease in the levels of proteins of the complex Q in various
mouse models of mitochondrial diseases [74], as well as in the muscle and adipose tissue
of patients and a mouse model with insulin resistance [75]. Furthermore, the levels of CoQ
are one of the mitochondrial factors involved in aging, and a specific review about this
topic was recently published [29].
Supplementation with exogenous CoQ10 is the main therapeutic strategy for these
pathologies. However, the therapeutic efficacy of CoQ10 supplementation is quite vari-
able [48,50,76,77], highlighting the need to look for new options. Thus, this review is
focused on describing the available animal models for CoQ deficiency that have been
used to date in the study of CoQ deficiencies (Table 1), how they have contributed to ex-
pand our knowledge about CoQ metabolism and the pathomechanisms of CoQ deficiency,
and how they may provide optimal therapeutic alternatives for patients suffering from
CoQ deficiencies.
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Table 1. Overview of the animal models of CoQ deficiency mentioned, remarking their contribution to expand the knowledge about the CoQ biosynthetic pathway and functions, and the
pathomechanisms and treatments related to CoQ deficiency.
Model Strain Phenotype
Coenzyme Q CoQ Deficiencies
Ref
Biosynthesis Functions Pathological Mechanisms Treatments
Drosophila
melanogaster
qless mutant Nervous systemfailure
Caspase-dependent
apoptosis in neurons
CoQ4, CoQ9 or CoQ10












CoQ10 partially rescue the
phenotype. [79,80]
Coq2 mutant Renal failure Larvallethality








Coq3 mutant Larval lethality Existence of complexQ




Coq5 mutant Larval lethality




Coq6 mutant Existence of complexQ DMQ accumulation [82,83]
Coq7 mutant Larval lethality Existence of complexQ




Coq8 mutant Larval lethality




Coq9 mutant Larval lethality Existence of complexQ




Coq10 mutant Larval lethality
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Table 1. Cont.
Model Strain Phenotype
Coenzyme Q CoQ Deficiencies
Ref
Biosynthesis Functions Pathological Mechanisms Treatments
Caernorhabditis
elegans
Mev-1 mutant Shortened lifespan





oxidized forms of CoQ
CoQ10 rescued the
phenotype. [84–86]
Clk-1 mutant Extended lifespan COQ7 has catalyticactivity.
CoQ10 has the highest
antioxidant properties.
Accumulation of DMQ9.
Lower production of ROS.














CoQ10 or feeding worms
with bacteria containing its













CoQ10 or feeding worms
with bacteria containing its













containing the own C.
elegans coq-3 gene rescue
the phenotype.
[92,94,95]
Coq8 mutant Larval lethality
CoQ is important in the
early stages of
development and fertility.
CoQ-rich diet increased its
lifespan [93,96]
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Table 1. Cont.
Model Strain Phenotype
Coenzyme Q CoQ Deficiencies
Ref
Biosynthesis Functions Pathological Mechanisms Treatments
Danio rerio
(zebrafish)
Clk-1 mutant Extended lifespan COQ7 has catalyticactivity.
CoQ10 has the highest
antioxidant properties.
Accumulation of DMQ9.
Lower production of ROS.














CoQ10 or feeding worms
with bacteria containing its













CoQ10 or feeding worms
with bacteria containing its













containing the own C.




Coq8 mutant Larval lethality
CoQ is important in the
early stages of
development and fertility.






greatest sensitivity to Pdss2
impairment
[97]
Pdss2f/-; Pax2-cre Cerebellar ataxia
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Table 1. Cont.
Model Strain Phenotype
Coenzyme Q CoQ Deficiencies
Ref
Biosynthesis Functions Pathological Mechanisms Treatments
Pdss2f/−; Pcp2-cre Cerebellar ataxia
Ataxia at old age.
Progressive decreased of














A small amount of CoQ is
required in the respiratory
chain function in liver.
Accumulation of DMQ9.












are not highly susceptible



















CoQ is important in the
early stages of
development.
Accumulation of DMQ [104,105]
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Table 1. Cont.
Model Strain Phenotype
Coenzyme Q CoQ Deficiencies
Ref
Biosynthesis Functions Pathological Mechanisms Treatments
Coq7+/− Extended lifespan
Decreased CoQ levels in the
inner mitochondrial membrane
coupled with higher CoQ levels
in the outer mitochondrial
membrane. Early hepatic
mitochondrial dysfunction,







in the stability of
complex Q.
Purkinje cells displayed Golgi
morphology defects, but normal
mitochondria. Model to study
CoQ production across different
organelles, cells, and tissues
[107]
Coq9Q95X Extended lifespan




sulfide oxidation pathway [108,109]
Coq9R239X Encephalopathy

















in the control of CoQ
levels.
Impairment in lipid metabolism CoQ partially recoveredthe phenotype. [115]
Parl−/− Encephalopathy






CIII-regulating protein TTC19 [116]
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2. Invertebrate Models of CoQ Deficiency
Invertebrate models have the great advantage of being easily generated and charac-
terized compared to vertebrate models. Thus, worms and flies lacking CoQ have been
produced, and they highlighted important functions of CoQ. However, invertebrate sys-
tems are not sufficient to reproduce the complexity of mammalian systems [117,118].
2.1. Fruit Fly Models: Drosophila Melanogaster
Drosophila melanogaster is commonly known as the fruit fly or vinegar fly [118]. It has
been widely used because it offers several advantages for the investigation of molecular
and cellular mechanisms due to its short lifespan, large number of offspring, and having a
genome that is easy to modulate [119]. Drosophila contains three CoQ forms with the follow-
ing approximated proportions: 5% CoQ8, 82% CoQ9, and 13% CoQ10. Those proportions
change depending on the age of the fly and the developmental stage [83].
Mutations in the Drosophila qless (cg31005) gene, an orthologue of the human PDSS1, in-
duce an upregulation of markers of mitochondrial stress and caspase-dependent apoptosis
in neurons. Full rescue of the qless neural phenotype was achieved by dietary supplementa-
tion with CoQ4, CoQ9, or CoQ10 [78]. Additionally, mutations in the Drosophila sbo (cg9613
or coq2) gene, homolog of the human COQ2, leads to a small larvae phenotype. The sbo
null mutants are developmentally arrested at the first instar larval stage. Flies that are het-
erozygous for sbo show reduced CoQ9 and CoQ10 production and a controversial extended
lifespan [79]. Coq2 mutant flies are more susceptible to bacterial and fungal infections,
while they are more resistant to viruses. The supplementation with CoQ10 partially rescues
the impaired immune functions of coq2 mutants because it restores the gene expression
of anti-microbial genes but increases the susceptibility to viral infection [80]. Moreover,
another Drosophila model with mutation in the coq2 gene was generated employing garland
cell nephrocytes (GCN) to model human COQ2 nephropathy. This study found that coq2 is
required for slit diaphragm morphology and function, since coq2 silencing causes large ar-
eas without slit diaphragms, while slit diaphragms densely populate the surface of control
GCN. Following, it was proved that the pathogenesis of coq2 is linked to mitochondrial
reactive oxygen species (ROS) formation because of the increased ROS formation in coq2
loss-of-function. According to that, the phenotype was rescued after the treatment of
coq2 flies with the ROS scavenger glutathione for 5 days, remarking the importance of
oxidative stress in the renal pathology associated to CoQ deficiency. Interestingly, this coq2
phenotype was also partially rescued by the supplementation with vanillic acid (VA) [81].
VA is an analog of the CoQ natural precursor, the 4-hydroxybenzoic acid (4-HB), which has
previously demonstrated its therapeutic activity in other models of CoQ deficiency [35,120],
although the therapeutic mechanism for defects in coq2 have not been clearly identified.
The UAS-GAL4 system for gene silencing with RNAi has been also used in Drosophila
to interfere with the expression of each of the CoQ biosynthetic genes [83]. The results
demonstrate that flies with RNAi against CoQ genes show a decrease in CoQ levels. The
percentage of decrease depends on the affected gene and the intensity of the gene silencing.
RNAi against the gene cg10585 (human PDSS2) showed the hardest phenotype with flies
arresting their development cycle after egg hatching. Gene interference of qless (cg31005),
coq2, coq3, coq5, coq7, coq8, coq9, or coq10 produced lethality at larvae or pupae development
stages. When the silencing gene was coq6, flies managed to achieve the adult fly stage but
suffered from severe CoQ deficiency. Demethoxyubiquinone (DMQ) was detected when
coq3, coq6, coq7, and coq9 were silenced, supporting the idea of a multi-enzymatic complex
for CoQ biosynthesis [82,83].
2.2. Worm Models: Caenorhabditis Elegans
Caenorhabditis elegans (C. elegans) has been extensively used as a model organism in
different fields of research [29,118]. The ability to inactivate a target gene transiently by
RNAi has greatly accelerated the analysis of loss-of-function phenotypes in C. elegans [121].
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A model of secondary CoQ deficiency in C. elegans is the mev-1 mutant strain, which
has a defect in complex II. This model shows a decrease in the CoQ9 levels and altered
rates of the reduced and oxidized forms of CoQ [84,118]. Mev-1 mutant also manifests a
disruption of the superoxide dismutase activity, leading to an accumulation of reactive
oxygen species (ROS) and a shorter lifespan compared to the wild type [85]. The supple-
mentation with CoQ10 rescues the phenotype by the reduction of superoxide anion level,
suggesting the link between lifespan and oxidative stress in mitochondria [86]. Models of
primary CoQ deficiency in C. elegans will be described below.
C. elegans clk-1 mutants are worms with primary CoQ deficiency. The clk-1 gene is
the homologous of the COQ7 gene in humans. As a result of this mutation, the clk-1
mutant shows a decrease in the CoQ9 levels and an accumulation of the intermediate
demethoxyubiquinone (DMQ9), the substrate of COQ7 [87], thus confirming the catalytic
reaction of this enzyme. Intriguingly, the phenotype is characterized by an increase in
the lifespan together with a slowed pharyngeal pumping and abnormalities in defecation,
movement, embryogenesis, and larvae development [89,122,123]. The reason for the
life extension seems to be a lower production of reactive oxygen species (ROS) due to a
reduction in the electron flow of the respiratory chain because of the inhibition of complex
I [118]. This hypothesis is based on (1) Clk-1 mutants showing a profound defect in complex
I+III activity, which contributes to ROS production and its link to lifespan [88]; and (2) the
accumulated DMQ9 in clk-1 mutant could inhibit complex I+III activity [90]. Nevertheless,
it is also important to take into account that either the small amount of CoQ9 synthesized
by clk-1 mutant and/or the CoQ8 coming from the diet would stabilize complex III and
determine the longevity of this model [87,118,124]. The supplementation with CoQ10 to
clk-1 mutant rescued the phenotype and returned the lifespan to wild-type levels [91,118].
Other studies in the clk-1 mutant indicated that CoQ10 is the CoQ isoform with higher
antioxidant properties because the clk-1 mutant feed with genetically engineered bacteria
that produce CoQ10 rescued the phenotype by lowering oxidative stress, while those fed
with bacteria that produce CoQ6, CoQ7, CoQ8, or CoQ9 had no effect [86,89,92,118].
C. elegans mutant strains VC479, VC752, and VC614 are available heterozygous mutant
strains with deletions in the genes coq-1 (allele ok749), coq-2 (allele ok1066), and coq-8 (allele
ok840), respectively. Coq-1, coq-2, and coq-8 knockouts arrested development during larval
stages L1–L2 (coq-1 mutants) or L4-adult (coq-2 and coq-8 mutants) [93]. Larval development
arrest was also reported for C. elegans coq-3 knockouts, pointing out the importance of
CoQ in the early stages of development [95]. The first generation of coq-1 and coq-2
knockouts had muscular atrophy due to cell death, apoptosis corpses, and eventual tissue
disorganization with paralysis of the posterior half of the larval body, which was probably
mimicking the encephalomyopathic form of CoQ deficiency [93]. Other coq-1, coq-2, and
coq-3 knockdown models mimic the cerebellar involvement of CoQ deficiency with an
age-dependent loss of motor coordination correlated with the progressive degeneration of
GABA neurons. However, other types of neurons in motor and sensory circuits that use
other neurotransmitters (dopamine, acetylcholine, glutamate, serotonin) and body muscle
cells were less sensitive to CoQ depletion [94]. The supplementation with exogenous CoQ10
or feeding worms with bacteria containing its own CoQ8 did not have a great impact on
phenotype improvement of coq-1, coq-2, or coq-3 mutants, suggesting that exogenous CoQ
has therapeutic limitations due to its limited bioavailability [92]. A full rescue of the
coq-3 mutant phenotype was achieved by an extra-chromosomal array containing the
own C. elegans coq-3 gene, illustrating the crucial role that the endogenous synthesized
CoQ9 isoform plays in fertility and development [92,118]. Alternatively, coq-8 mutants
increased their lifespan if they were fed with a CoQ-rich diet with wild-type E. coli, but no
improvement was observed in fertility [96].
3. Vertebrate Models of CoQ Deficiency
Vertebrate models of CoQ deficiency, especially the mammalian ones, are helpful to
study the physiopathology of CoQ deficiencies and to understand the heterogeneity of
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these syndromes because they mimic the cellular functions of CoQ, the biosynthesis, its
regulation, and the tissue specificity that may exist in humans. That is the reason why
these models are also useful in preclinical studies to test new therapies [117].
3.1. Zebrafish Models of CoQ Deficiency
Zebrafish biology allows ready access to all developmental stages, and the optical
clarity of embryos and larvae allow real-time imaging of developing pathologies. Sophis-
ticated mutagenesis and screening strategies on a large scale, and with a cost that is not
possible in other vertebrate systems, have allowed the generation of zebrafish models for a
wide variety of human diseases [125].
The generation of a zebrafish model with a null allele in ubiad1, called barolo (bar),
produced a phenotype with specific cardiovascular failure due to oxidative stress and
ROS-mediated cellular damage [126]. Ubiad1 is considered as a nonmitochondrial prenyl-
transferase responsible for the synthesis of CoQ10 in the Golgi membrane compartment
in zebrafish [31,126]. As a result of that, the bar mutants showed a depletion in the CoQ10
levels in the cytosol. The accumulation of ROS reported in the bar mutants increased
the lipid peroxidation in vascular cells, leading to the cardiovascular oxidative damage
characteristic of this model. Moreover, the inhibition of eNOS rescued the oxidative dam-
age previously described, suggesting a specific role of Ubiad1 on the regulation of NO
signaling. Additionally, in the same study, they knocked-down Coq2 expression during
zebrafish development. Loss of Coq2, the mitochondrial prenyltransferase involved in
CoQ10 biosynthesis, leads to oxidative stress, but it does not significantly affect vascular
integrity and survival. Comparing both zebrafish models, the authors found that the
Coq2-mediated CoQ10 production is mainly for mitochondrial respiratory chain function
and energy production; whereas Ubiad1-mediated CoQ10 production is important for
membrane redox signaling and protection from lipid peroxidation [126]. UBIAD1 is also a
novel vitamin K2 biosynthetic enzyme screened and identified from the human genome
database [127]. Another ubiad1 mutant (reddishs587) was generated to demonstrate the
essential role of the vitamin K2 generated by Ubiad1 in the maintenance of the endothelial
cell function and overall vascular homeostasis. The treatment with vitamin K2 rescued the
vascular phenotype of ubiad1 mutant reddishs587 but not the cardiac phenotype, suggesting
that an alternative Ubiad1/vitamin K-independent pathway may participate in the cardiac
function [128].
In other series of experiments, morpholino oligonucleotide (MO) knockdown of
Coq6 or Coq8b (=Adck4) in zebrafish caused apoptosis in the Coq6 knockdown zebrafish
embryos [57] and nephrosis phenotype of periorbital and total body edema in the Coq8b
knockdown zebrafish embryos [63], mimicking the nephrotic syndrome phenotype of
the patients.
In addition to those already characterized models, the Zebrafish Mutation Project
seems to have generated different zebrafish models with mutations in Coq genes (https:
//zmp.buschlab.org/search/coq; accessed on 26 September 2021), although none of these
models have been characterized so far.
3.2. Mouse Models of CoQ Deficiency
3.2.1. Mouse Models with Spontaneous Mutation
The polyisoprenyl diphosphate synthase is the enzyme responsible for the formation
of the isoprenyl side chain of CoQ in mice and humans. It is a heterotetramer composed
of two protein subunits. The genes that encode these subunits are designated Pdss1
and Pdss2 in mice, and PDSS1 and PDSS2 in humans [97,129]. A mutation in Pdss2
was reported in mice with inherited kidney disease. The mutation arose spontaneously
in an inbred strain of mice, which appeared to be due to an autosomal recessive gene,
and it was designated ‘kidney disease’ (kd) [117,130]. The first clinical manifestations
were developed at 10 weeks of age, and it was characterized by increased proteinuria.
This was followed over several weeks by excessive drinking, dilute urine, loss of weight,
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anemia, and death in 5 to 7 months. Histological examination of kidneys at earlier age
reveals kidney damage due to mononuclear cell infiltrate and tubular dilatation with
proteinaceous casts in cortical areas, which with time expands throughout the entire kidney
and leads to renal failure [130]. Initial studies prior to the identification of the genetic defect
suggested an autoimmune mechanism as the pathophysiological mechanism behind this
syndrome [131,132]. However, this hypothesis was discarded, as it was proved that the
immune response was a secondary consequence of the genetic defect of kd/kd mice [133].
Kd/kd mice developed a typical nephrotic syndrome with the characteristic biochemical
perturbations in serum accompanied by albuminuria and visceral epithelial abnormalities,
including hyperplasia and podocyte effacement [117,134].
A positional cloning approach demonstrated that the kd allele is a missense mutation in
Pdss2 gene (Pdss2kd/kd), showing that the failure in the coenzyme Q biosynthetic pathway is
the cause of a lethal kidney disease in mice [135]. The kd/kd mutation (V117M) occurs within
the conserved domain I of Pdss2, and the levels of CoQ9 and CoQ10 in kidney homogenates
from Pdss2kd/kd were significantly lower than in control mice [97]. The Pdss2 mutant mice
manifested widespread CoQ deficiency and abnormalities in the mitochondrial respiratory
chain. However, other parameters such as ROS production, oxidative stress, mitochondrial
DNA depletion, and citrate synthase activity, an index of mitochondrial mass, appeared
only in affected organs. Those data suggested that kidney-specific loss of mitochondria
triggered by oxidative stress may be the cause of renal failure in Pdss2kd/kd mice [136].
Additionally, the impairment of the sulfide oxidation pathway induced by decreased levels
of CoQ has been proposed as a pathophysiological mechanism under this syndrome. The
disruption in the sulfide oxidation pathway caused the following: (1) accumulation of
sulfides due to the decreased levels of SQOR and downstream enzymes, (2) low levels of
plasma and urine thiosulfate, (3) the inhibition of short-chain acyl-CoA dehydrogenase,
and (4) the decreased levels of glutathione, which may partially avoid the scavenge of
hydrogen peroxide, thus contributing to oxidative damage and structural and functional
alteration of the renal glomerulus [15,137].
Oral supplementation with CoQ10 induces a rescue of proteinuria and interstitial
nephritis in the Pdss2kd/kd mutant mice through the normalization of different CoQ func-
tions [138,139]. Additional studies demonstrated that probucol had a more powerful health
improvement than high-dose CoQ10 supplementation and was able to restore CoQ9 content
in the kidneys of Pdss2kd/kd mice [140]. In addition, rapamycin administration was able
to reduce the proteinuria in Pdss2kd/kd mice [141], and the treatment with GDC-0879, a
Braf/Mapk-targeting compound, ameliorated renal disease in Pdss2kd/kd mice, which was
probably through a mechanism that involves the activity of GPx4 [142].
3.2.2. Conditional Knockout Mouse Models
To further evaluate the nephrotic phenotype associated with CoQ deficiency, tissue-
specific conditional Pdss2 knockout (KO) mice were generated [97,117]. The deletion of
Pdss2 was targeted to renal glomerular podocytes in Podocin/cre,Pdss2loxP/loxP, renal tubular
epithelium and hepatocytes in PEPCK/cre,Pdss2loxP/loxP, monocytes in LysM/cre,Pdss2loxP/loxP,
and hepatocytes in Alb/cre,Pdss2loxP/loxP. Interestingly, the kidney disease phenotype ap-
peared only in Podocin/cre,Pdss2loxP/loxP KO mice but not in the other conditional KO, as
estimated by albuminuria and morphological evidence of nephritis (dilated tubules and
extensive interstitial infiltration). These data suggested that the renal glomerular podocytes
are particularly sensitive to the dysfunction of PDSS2. In fact, knocking out the Pdss2
gene in podocytes resulted in a more severe phenotype than that observed in Pdss2kd/kd
mice, indicating that the product of the missense allele in Pdss2kd/kd has some residual ac-
tivity. The liver-conditional Alb/cre,Pdss2loxP/loxP KO mice did not show detectable levels of
CoQ9 in the liver, leading to impaired mitochondrial respiration and altered intermediary
metabolism as demonstrated by transcriptional profiling and amino acid quantitation [97].
Nevertheless, Alb/cre,Pdss2loxP/loxP KO mice did not develop any symptoms of disease.
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In addition to kidney, cerebellum is one of the most often affected organs in CoQ
deficiency [143], and cerebellar atrophy has been diagnosed in many infants with this
disease. In order to analyze the cerebellum defect in CoQ deficiency, a Pdss2 conditional
KO (Pax2/cre,Pdss2f/-) was generated crossing a previously generated Pdss2 floxed mouse
(Pdss2f/f) with a Pax2-cre deleter mouse, in which Cre recombinase is expressed in the hind-
brain region at E9.5 and influences many cells in the cerebellum at birth [98]. Pax2/cre,Pdss2f/-
died within the first 36 h of life and suffered from cerebellar hypoplasia and cellular disor-
ganization in the cerebellum, which mimics the cerebellum atrophy commonly observed in
CoQ-deficient infants. This macroscopic observation was accompanied by inhibition of cell
migration and cell proliferation as well as increased ectopic apoptosis in the cerebellum of
Pdss2 KO embryos [98]. A different specific deleter mouse Pcp2-cre [144] was also crossed
with a Pdss2f/f mouse to generate another tissue-specific KO mouse (Pcp2/cre,Pdss2f/−). In
this last Pdss2 mutant model, the mutation was developed only in cerebellum Purkinje
cells after birth. Pcp2/cre,Pdss2f/− was clinically healthy and with normal behavior until
4.5 months. From this time, an ataxic phenotype at old age was manifested due to the
progressive decrease of Purkinje cells and initiation of diffusive neuron death by apoptosis,
showing at 9.5-month loss in motor coordination and incapability of maintaining body
balance on a rod. Thus, this last conditional KO mouse model may be a better model to
study the cerebellar defects linked to CoQ deficiency in adulthood [98].
As steroid-resistant nephrotic syndrome (SRNS) has been linked to mutations in
several genes encoding CoQ biosynthetic enzymes [52,54,57,63], a podocyte-specific Coq6
KO mouse model was generated by crossing Podocin-cre mice with Coq6loxP/loxP mice in
which two loxP sites surround exon 6 in the Coq6 gene. The COQ6 protein is an hydroxylase
that seems to catalyze two uncharacterized hydroxylation steps in CoQ biosynthesis [129].
The Coq6 KO model is referred as Nphs2/cre,Coq6loxP/loxP KO mice, also Coq6podKO [99].
Coq6podKO mice appeared to be normal in development and body condition until the age of
5 months, when they deteriorated, gradually developing progressive glomerular sclerosis
and proteinuria. They became moribund at 10 months of age with advanced decline of
renal function. Interestingly, the administration of 2,4-dihidroxibenzoate acid (2,4-diHB),
a CoQ10 precursor analogue, to 5-month-old Coq6podKO mice significantly protected from
disease progression, and the survival was comparable to that of control mice. With the
2,4-diHB treatment, proteinuria and renal histology improved dramatically in treated
Coq6podKO mice compared with untreated Coq6podKO mice [99]. However, the therapeutic
mechanisms of 2,4-diHB in this model are unclear, and the levels of CoQ after the treatment
were not reported.
As mutations in ADCK4 (COQ8B) have been also reported in patients with SRNS, a
similar study was carried out to evaluate the role of Adck4 in kidney function. For that
purpose, a podocyte-specific Adck4 KO mouse was generated. Known as Adck4tm1d or
Nphs2/cre, Adck4flox/flox (also Adck4∆Podocyte) was generated by crossing the Nphs2-cre mouse
with the Adck4flox/flox mouse in which two loxP sites surround exons 5 and 6 in the Adck4
gene. Adck4∆Podocyte developed an increased in adult morbidity, mortality, and weight loss
with progressive albuminuria and renal structural abnormalities (focal segmental glomeru-
losclerosis with extensive interstitial fibrosis and tubular atrophy) and functional decline.
Treatment of 3-month-old Adck4 KO mice with 2,4-diHB prevented the development of
renal pathology and reversed mitochondrial dysfunction. Again, the CoQ levels after
2,4-diHB therapy were not reported, so the therapeutic mechanisms were unknown. Nev-
ertheless, these data suggest that ADCK4, an uncharacterized mitochondrial protein with
no enzymatic activity directly involved in the CoQ biosynthetic pathway, must be a protein
component in CoQ biosynthesis [100]. The rescue in the phenotypes of the Coq6podKO and
Adck4∆Podocyte KO mice after the treatment with 2,4-diHB suggests a potential treatment
strategy for nephrotic syndrome resulting from COQ6 and ADCK4 mutations.
Separately, the Coq7(=Mclk1)liver-KO mouse was generated. This model carried a
liver-specific KO mutation in the Coq7 gene. The quinone measurements in the liver
of Coq7liver-KO showed that CoQ9 levels were decreased by 85% and DMQ9 was substan-
Antioxidants 2021, 10, 1687 16 of 27
tially accumulated, which is consistent with a dysfunctional COQ7 activity. This decrease
in CoQ in hepatocytes caused only a mild reduction of the mitochondrial respiratory chain
function and no gross abnormalities, suggesting a nonlinear dependence of mitochondrial
respiratory capacity on CoQ content. In addition, these results suggest that very little CoQ
is required in this process. Moreover, DMQ seems not to interfere with CoQ-mediated mi-
tochondrial electron transport in the liver. The supplementation with CoQ10 to Coq7liver-KO
increased the CoQ10 content in the liver and partially rescued the electron transport deficit
in this tissue [101]. Later on, a global conditional KO mouse model for the Coq7 gene
was generated by expressing tamoxifen TM-dependent CreERT2 transgene. Following the
induction of Coq7 KO by TM at two months of age, adult-onset global Coq7 KO (aogCoq7)
animals gradually accumulated DMQ and lost CoQ, leading to mitochondrial dysfunction
and shortened lifespan. Interestingly, during the time that Coq7 KO mice started to die, the
levels of CoQ were very low in the heart. However, cardiac function was not compromised,
suggesting that this tissue has a CoQ reservoir. Dietary CoQ10 was ineffective in rescuing
the phenotype of Coq7 KO mouse mice, but the supplementation with 2,4-diHB produced
a partial restoration of mitochondrial respiration and led to a marked increase in their
survival [102]. In this particular case, the therapeutic mechanism was attributed to the
increase in CoQ and decrease in DMQ, as 2,4-diHB is able to bypass defects in COQ7. This
result highlighted the important clinical implications of the treatment with 2,4-diHB also
in COQ7 mutations. Furthermore, a late-onset treatment with 2,4-diHB 6 months after TM
induction, a moment in which the untreated KO mice show apparent phenotypes, was also
able to increase the survival the Coq7 KO mice [102].
3.2.3. Constitutive Knockout and Knock-In Mouse Models
In addition to the mouse models with spontaneous mutation and the conditional KO
mouse models of CoQ deficiency previously described, some constitutive KO and knock-in
(KI) models have been generated to date.
The KO for Pdss2 (B6.Þp3/cre,Pdss2loxP/loxP) was embryonically lethal, with no ho-
mozygous embryos surviving beyond 10.5 days of gestation [97], which is consistent with
the hypothesis that ubiquinone is essential for mouse embryonic development [98,104].
Similar results were obtained with the constitutive KO mouse for Coq3 [103]. COQ3 is
an O-methyltransferase responsible for the first and last O-methyltransferase steps in
CoQ biosynthesis [145]. Coq3−/− resulted in embryonic lethality, as no Coq3 homozygous
mice were obtained from heterozygous crosses [103]. However, Coq3 heterozygous mouse
(Coq3+/−) showed normal lifespan and no changes in CoQ levels in pure mitochondria
isolated from 3-month-old Coq3+/− livers [103].
Similar to Pdss2 and Coq3 KO, two independently generated KO models of Coq7
showed embryonic lethality [104,105]. In one case, the Coq7−/− embryos failed to sur-
vive beyond E10.5, exhibiting small-sized body and delayed neural development. These
results suggest that COQ7-deficient embryos are able to develop until E8 with the en-
ergy generated from anaerobic glycolysis, but they are unable to survive due to the lack
of aerobic glycolysis required for further embryogenesis in mice. Electron microscopic
analysis showed a loss of organized neuroepithelial structures in Coq7−/− embryos and
enlarged mitochondria with vesicular cristae and enlarged lysosomes filled with disrupted
membranes, demonstrating that COQ7 is essential for neurogenesis and for the mainte-
nance of mitochondrial integrity [105]. In the other study, the Coq7−/− embryos showed
a developmental delay that was evident by E9.5, and all Coq7−/− embryos detected were
completely resorbed by E13.5 [104]. Consistent again with a dysfunctional COQ7 protein,
the embryos of both KO Coq7 mice showed reduced CoQ levels and accumulation of DMQ,
highlighting the crucial role of COQ7 in the CoQ metabolism [104,105].
On the other hand, heterozygous Coq7+/− mice were viable and fertile with no obvious
anatomical or behavioral defects [104]. The amounts of CoQ9 and CoQ10 were similar
in wild-type and heterozygous embryos. Young Coq7+/− mutants showed reduced mito-
chondrial oxygen consumption, reduced electron transport, reduced mitochondrial ATP
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synthesis, reduced mitochondrial and overall ATP levels, and reduced whole-animal oxy-
gen consumption [146]. Moreover, it was discovered that in the livers of very old Coq7+/−
mutants, a phenomenon of loss-of-heterozygosity took place because there were areas of
complete loss of expression of Coq7. That was followed by a decrease in the CoQ levels
in the livers of very old Coq7+/− mutants [103,146]. Furthermore, it has been reported
that Coq7+/− mice present a unique mitochondrial CoQ profile that was characterized by
decreased CoQ levels in the inner mitochondrial membrane coupled with higher CoQ
levels in the outer mitochondrial membrane. The low levels of CoQ in the inner membrane
could increase oxidative stress by partially inhibiting the electron transport chain. At the
same time, similar amounts of total CoQ were detected in the mitochondrial, peroxisomal,
and plasma membrane fractions from Coq7+/− and control mice livers at three months of
age. Dietary supplementation of Coq7+/− mice with CoQ10 normalized the CoQ levels in
the inner mitochondrial membrane and in the outer mitochondrial membrane as well as
the respiratory chain dysfunction [103]. Interestingly, Coq7+/− mice showed an increase
in lifespan up to 31%, as it was reported in the mutational inactivation of its orthologue
clk-1 in C. elegans, with significantly lower levels of DNA damage [106]. The increase
in the lifespan in Coq7+/− mice has been associated with an early hepatic mitochondrial
dysfunction, which induces a protective physiological response called mitohormesis [106].
The mechanisms underlying the increased lifespan in Coq7+/− mice include the following:
(1) Despite the early mitochondrial dysfunction, the function of Coq7+/− mitochondria
declines less rapidly with age than that of the wild type, and there is a slower accumulation
of global oxidative biomarkers of aging in these mutants [147].
(2) The altered mitochondrial phenotype of Coq7+/− mutants enhanced immune re-
action to infection by improving basal and stimulated expression of HIF-1α in liver and
macrophages, in association with elevated expression of inflammatory cytokines [148].
(3) Coq7+/− mutants have enhanced resistance to neurological damage after ischemia
and reperfusion [149].
Finally, a recent study in Coq7+/− mutants suggested that Coq7 regulates microglial
metabolic reprogramming participating in neuroinflammation and dopaminergic cell
death [150].
In contrast with the Coq gene KOs previously mentioned, the lack of COQ8A in mice
(Coq8a−/−) resulted in a mild phenotype with progressive cerebellar ataxia, mild exercise
intolerance, and moderate CoQ deficiency, recapitulating the more frequent features of
autosomal-recessive cerebellar ataxia type 2 (ARCA2, the most frequent form of hereditary
CoQ deficiency in humans) [107]. The pathophysiology of the disease was linked to
dysfunctional cerebellar Purkinje cells, defective skeletal muscle, and disruption of complex
Q. Coq8a−/− mice develop mild, tissue-specific CoQ deficiency. The levels of CoQ were
low in skeletal muscle of Coq8a−/− mice, while normal CoQ levels were observed in
whole Coq8a−/− cerebellum. These data suggest that CoQ deficiency may specifically
affect the Purkinje cells of the cerebellum, although the specific measurement of CoQ in
those cells was not performed. Additionally, complex Q proteins were deficient across
multiple Coq8a−/− tissues, showing that COQ8A participates in the stability of complex Q
in mammals. Moreover, Coq8a−/− Purkinje cells displayed Golgi morphology defects, but
normal mitochondria, providing a model system to study CoQ production across different
organelles, cells, and tissues [107].
Another mouse model with intriguing results is the KO model for Coq9 (Coq9Q95X),
which had normal development, in contrast with the embryonic lethality described in Pdss2,
Coq3, and Coq7 KO mice. The Coq9Q95X mouse model was generated by the Wellcome
Trust Sanger Institute from ES cell clone EPD0112_2_A09 obtained from the supported
KOMP Repository (www.komp.org; accessed on 26 September 2021). Lack of the COQ9
protein caused moderate CoQ deficiency; i.e., the cerebrum, cerebellum, and heart showed
around 50% residual CoQ9 levels, while the kidney and skeletal muscle had 30% of residual
CoQ9 levels compared with wild-type mice. This led to a reduction in CI+III activity and
mitochondrial respiration in skeletal muscle and late-onset mild mitochondrial myopathy
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with exercise intolerance in female mice. The COQ9 protein is needed for the stability and
activity of COQ7 in the CoQ biosynthetic pathway, so the brain, kidneys, and muscles of
Coq9Q95X mice also showed a decrease in the levels of COQ7 [108]. As in other animal
models with a decrease in the COQ7 levels [146,151], Coq9Q95X mice showed an increase in
lifespan, especially in males because they lived on average 15% longer than their wild-type
littermates. The increase in lifespan in Coq9Q95X mice is accompanied by a reduction in
the animals’ body weight [109]. However, unlike Coq7+/− mice, the liver of Coq9Q95X mice
showed normal levels of CoQ levels; consequently, mitochondrial function was also normal
in this tissue. Therefore, unlike Coq7+/− mice, the hepatic mitochondrial dysfunction
and increased oxidative stress induced by subphysiological levels of CoQ biosynthetic
proteins are not the cause of the increased lifespan in Coq9Q95X mice. These effects could
be mediated by mechanisms initiated in the mitochondria from other tissues or by other
unknown mechanisms [109].
To better understand the pathomechanisms of primary CoQ deficiency due to a
mutation in the Coq9 gene, a knock-in mouse model carrying a homozygous mutation
in Coq9 gene was generated (Coq9R239X) [45]. The Coq9R239X mice encoded the mutation
CGT > TGA (R239X) within exon 7 in the mouse genome, which is a homologue to the
human R244X mutation described in a patient with CoQ10 deficiency [64]. In contrast
with the Coq9Q95X mouse, the Coq9R239X model manifested severe CoQ deficiency; i.e., the
CoQ9 levels were 15–20% compared to wild-type animals. The deficit in CoQ induced
a decrease in mitochondrial respiration, particularly in the brain and kidneys. These
effects lead to neuronal death and demyelination with spongiosis and astrogliosis in the
brain of Coq9R239X mice, leading to a premature death [45,108]. In tissues from Coq9R239X
mice, a truncated version of the COQ9 protein was detected, leading to a reduction in the
COQ7 protein and, as a consequence, a widespread CoQ deficiency and accumulation of
DMQ [45,108]. The truncated version of COQ9 protein in Coq9R239X mice destabilizes the
complex Q and produces a severe phenotype associated with fatal encephalomyopathy.
Therefore, the stability of the complex Q clearly influences the CoQ biosynthesis rate
and, consequently, the degree of the severity of CoQ deficiency and the development
of tissue-specific phenotypes [108]. Moreover, the disruption of mitochondrial sulfide
oxidation has been identified as one of the pathomechanisms associated to CoQ deficiency
in both Coq9Q95X and Coq9R239X mice [110], similarly to the Pdss2kd/kd mice [15]. Specifically,
severe CoQ deficiency caused a remarkable reduction in SQOR levels and activity, and
this deficit induced changes in the mitochondrial sulfide metabolism. In the brain of
Coq9R239X mice, the low SQOR levels produced an increase in downstream enzymes as well
as adjustments in the levels of thiols. As a result, the biosynthetic pathways of glutamate,
serotonin, and catecholamines were altered in the cerebrum, and the blood pressure was
reduced [110]. Additionally, CoQ deficiency in Coq9R239X mice also affected the sulfide
biosynthetic pathway (also known as the transsulfuration pathway), independently of
the availability of sulfur amino acids. In the kidneys of Coq9R239X mice, the levels of
cystathione-β-synthase, an enzyme of the transsulfuration pathway, marginally increased
compared with the control mice, and this variation was maintained under supplementation
with N-acetylcysteine or a sulfur amino acids restriction diet, displaying the tight regulation
between the biosynthetic and catabolic pathways of sulfide metabolism [111].
Oral supplementation with ubiquinone-10, the oxidized form of CoQ10, had limited
efficacy in the treatment of the Coq9R239X mouse model due to its poor absorption and
bioavailability. The supplementation with ubiquinol-10, the reduced form of ubiquinone-10,
provided better therapeutic results. It increased the levels of CoQ10 in tissue homogenates
and cerebral mitochondria, which results in an increase in CoQ-dependent respiratory
chain activities, reduction in the spongiosis, astrogliosis, and oxidative stress in differ-
ent brain areas, and an increase in body weight. These data suggest that water-soluble
formulations of ubiquinol-10 are a better option than ubiquinone-10 for the treatment of
primary CoQ10 deficiency [112]. Looking for alternative strategies to the classical exoge-
nous CoQ10 supplementation with the aim of increasing the endogenous CoQ biosynthesis,
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the therapeutic potential of 2,4-diHB (β-resorcylic acid or β-RA in the study) was also
tested in Coq9R239X mice [113,152]. Remarkably, the treatment in Coq9R239X mice increased
the lifespan to values close to the lifespan in wild-type mice. Moreover, while the maximal
survival of Coq9R239X mice treated with ubiquinol-10 was 17 months of age, the lifespan
achieved by 2,4-diHB reached a maximum of 25 months of age [113]. 2,4-diHB supple-
mentation rescued the phenotype of Coq9R239X mice, as shown by the reduction in the
histopathological signs of the encephalopathy, i.e., the spongiosis and reactive astrogliosis.
Those effects were mainly linked to the decrease in the levels DMQ9 and the increase in
mitochondrial bioenergetics in peripheral tissues. However, even if the CoQ biosynthesis or
the mitochondrial function did not change in the brain after the therapy, the Coq9R239X mice
showed an almost absence of cerebral vacuoles and reactive astrocytes after the 2,4-diHB
treatment. The authors suggested the hypothesis of a possible tissue–brain cross-talk, but
further studies are needed to reveal how the peripheral tissues communicate with the brain
in this situation [113,152].
Two other therapeutic strategies have been tested using the Coq9R239X mouse model or
cells from this mouse model. Firstly, the use of a lentiviral vector (CCoq9WP) allowed the
ectopi over-expression of Coq9 in mouse embryonic fibroblasts (MEFs) and hematopoietic
progenitor cells (HPC), leading to the restore of the CoQ biosynthetic pathway and mito-
chondrial function [114]. Secondly, researchers tested the therapeutic effects of rapamycin
administration in Coq9R239X mice [153] based on other studies that had demonstrated
the therapeutic benefits of rapamycin therapy in a few mouse models of mitochondrial
diseases [154,155]. Neither a low nor a high dose of rapamycin were able to increase the
mitochondrial bioenergetics, to reduce the spongiosis and reactive astrogliosis, and to
rescue the phenotypic characteristics of Coq9R239X mice, resulting in the lack of efficacy for
increasing the survival [153].
Recently, a heterozygous Adck2 KO mouse model (Adck2+/−) has been generated to
clarify the role of ADCK2 in CoQ biosynthesis and to explain the pathological mechanisms
involved in the disease caused by a mutation in this gene. While Adck2−/− mice are
embryonically lethal, Adck2+/− mice partially recapitulated the phenotype of a human
patient characterized by an adult-onset myopathy due to CoQ deficiency and an overall
defect in mitochondrial lipid metabolism. The quinones determination showed a significant
decrease in CoQ9 and CoQ10 levels in the skeletal muscle of Adck2+/−, leading to a decrease
in mitochondrial complex I+III and II+III activities and oxygen consumption rate. These
results suggest that ADCK2 deficiency impaired the normal mitochondrial respiratory
chain function in skeletal muscle, ultimately leading to mitochondrial dysfunction. Further
transcriptomics and metabolomics analysis supported the hypothesis that ADCK2 plays
an important role in the energy homeostasis in skeletal muscle. Based on these data, it was
proposed that ADCK2 is involved in the regulation of mitochondrial fatty acid β-oxidation
and CoQ levels in skeletal muscle. The supplementation with CoQ10 partially rescued the
phenotype of Adck2+/− mice, indicating the possibility of improving some of the defects
stemming from CoQ deficiency due to Adck2 mutation [115].
A mouse model of secondary CoQ deficiency of genetic origin is also available [116].
PARL is a protease located in the inner mitochondrial membrane with relevant but un-
clear physiological roles. However, it is related to different prevalent human diseases,
including cancer and neurodegenerative diseases, highlighting its biological significance
in pathological conditions [156]. Parl−/− mice developed a necrotizing encephalomyopa-
thy closely resembling Leigh syndrome. Mitochondria from the brain of Parl−/− mice
showed progressive structural alterations and early deficiencies of complex III (CIII) and
CoQ, resulting in a disruption of the mitochondrial calcium metabolism. A mitochondrial
proteome analysis in the brain of the PARL-deficient mice showed downregulation of the
CIII-regulating protein TTC19, several proteins required for CoQ biosynthesis, and SQOR.
The disruption in the COQ4 levels was detected in Parl−/− brains already at one week of
age. Subsequently, a downregulation of COQ3, COQ5, COQ6, COQ7, COQ9, and SQOR
was also observed. As a conclusion, the data indicated that the stabilization of TTC19 and
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the following regulation of CIII activity is mediated by PARL as well as the maintenance of
COQ4 expression in the brain, supporting CoQ biosynthesis in this organ. Nevertheless,
further studies are needed to explain the connection between the disruption in PARL and
in COQ4 and the resulting CoQ deficiency in the brain [156].
4. Conclusions and Perspectives
Primary CoQ deficiency is caused by mutations in any of the genes involved in the
CoQ biosynthetic pathway. Clinically, CoQ deficiency is a heterogeneous disease in humans,
which is linked to five major phenotypes and some other clinical symptoms. The clinical
heterogeneity and the variety of functions associated with CoQ complicate the description
of the pathomechanisms underlying this mitochondrial disease as well as the development
of new therapies. For that reason, several animal models with CoQ deficiency have been
generated, providing very useful insights, such as: (1) they have confirmed the involvement
of the target proteins in CoQ biosynthesis in different species, indicating the evolutionary
conservation of the pathway; (2) they have clearly shown the importance of CoQ during
development and its role in the mitochondrial respiratory chain, sulfide metabolism, and
pyrimidine metabolism; (3) they have revealed that the genotype–phenotype association,
the bioenergetics defect, the increased oxidative stress, and the disruption of sulfide and
pyrimidine metabolism are key disease pathomechanisms that may explain, at least in part,
the tissue specificities and the clinical heterogeneity; (4) they have shown the limitation of
the exogenous CoQ10 therapy, especially in some particular phenotypes; and (5) they have
opened promising therapeutic strategies based on the supplementation with 4-HB analogs.
However, some functional roles of CoQ have not been evaluated yet in the context of CoQ
deficiency. In addition, the therapeutic mechanisms of 2,4-diHB in some models seem
to be independent of the CoQ biosynthetic pathway, increasing the potential relevance
of this compound in the clinical practice. Furthermore, the development of other animal
models is required to cover the study of this complex syndrome and the different functions
of CoQ, and to elucidate the synthesis of CoQ in mammals. This is especially important,
for example, in the case of CoQ deficiency due to mutations in the COQ2 gene. In vitro
studies have demonstrated the therapeutic potential of the natural precursor of CoQ, 4-
hydroxybenzoic acid (4-HB) [157], but there is no available mouse model with mutation in
Coq2 to extend the study, limiting the potential translation of this treatment into the clinic.
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